ID: ALA145788

Max Phase: Preclinical

Molecular Formula: C27H28N8O3

Molecular Weight: 512.57

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(CCCNC(=O)c1cccc2nc3ccccc3nc12)CCCNc1n[n+]([O-])c2ccccc2[n+]1[O-]

Standard InChI:  InChI=1S/C27H28N8O3/c1-33(18-8-16-29-27-32-35(38)24-14-5-4-13-23(24)34(27)37)17-7-15-28-26(36)19-9-6-12-22-25(19)31-21-11-3-2-10-20(21)30-22/h2-6,9-14H,7-8,15-18H2,1H3,(H,28,36)(H,29,32)

Standard InChI Key:  ABBOYNNIYCUFHP-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 512.57

Molecular Weight (Monoisotopic): 512.2284

AlogP: 2.15

#Rotatable Bonds: 10

Polar Surface Area: 136.92

Molecular Species: BASE

HBA: 8

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 7.50

CX Basic pKa: 9.41

CX LogP: 2.11

CX LogD: 0.11

Aromatic Rings: 5

Heavy Atoms: 38

QED Weighted: 0.13

Np Likeness Score: -0.70

References

1. Hay MP, Pruijn FB, Gamage SA, Liyanage HD, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA..  (2004)  DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.,  47  (2): [PMID:14711317] [10.1021/jm030399c]

2. Cascioferro S, Parrino B, Spanò V, Carbone A, Montalbano A, Barraja P, Diana P, Cirrincione G..  (2017)  An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds.,  142  [PMID:28851503] [10.1016/j.ejmech.2017.08.009]

Source

Source(1):

• Scientific Literature